Walgreen’s has reported fiscal fourth quarter results, showing continued prescription growth and highlighting its broader wellness and health management efforts.
Having taken heat on drug safety, the FDA has issued a new draft guidance on risk mitigation efforts by drug companies.
In another personalized medicine development, researchers at UCLA have identified a way to improve depression treatment.
A recent drug trial illustrates how comparative effectiveness research may actually facilitate more health care spending.
Pharmacogenomics is at the forefront of personalized medicine development. Recent research indicates promise in anti-platelet therapy guidance.
A recent report from NEHI states that medication therapy non-compliance leads to $290 billion in avoidable medical costs every year.
The physical distribution and payment flows for pharmaceuticals in the United States are very complex. A new report helps explain those processes.
An article examines barriers to physician participation in medical research.
The three largest PBMs have issued their second quarter results. All appear to be performing well.
Between lobbying and price increases, drug manufacturers are doing a good job of protecting their economic interests.
A study indicates that patients who receive medical care and prescriptions at the worksite tend to be more compliant with their drug regimens.
The limiting of growth in drug spending is a health care success story.